Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial

por Urbonas, V, Schadendorf, D, Zimmer, L, Danson, S, Marshall, E, Corrie, P, Wheater, M, Plummer, E, Mauch, C, Scudder, C, Goff, M, Love, S B, Mohammed, S B, Middleton, M R
Publicado 2019